Key Takeaways
- • Special purpose acquisition company Drugs Made In America Acquisition Corp. has filed regulatory plans to merge with AI platform Power Analytics Global Corp. in a transaction valuing Power Analytics at $1 billion enterprise value.
- • The SPAC merger represents a strategic convergence between domestic pharmaceutical manufacturing and artificial intelligence technology capabilities.
- • Deal structure involves a regulatory filing with U.S. authorities, indicating formal progression toward closing the combination.
Summary
Drugs Made In America Acquisition Corp., a special purpose acquisition company, has announced plans to merge with Power Analytics Global Corp., an AI-focused technology platform, according to regulatory filings submitted to U.S. authorities on May 6, 2026. The transaction is structured with Power Analytics carrying a target enterprise valuation of $1 billion.
The SPAC merger represents a notable pairing of a domestic pharmaceutical manufacturing focus with artificial intelligence and analytics capabilities. Power Analytics Global Corp.'s technology platform would complement the strategic objectives of the Drugs Made In America initiative, which emphasizes domestic production and supply chain resilience in the pharmaceutical sector.
The filing of merger plans with U.S. regulators indicates the transaction has advanced to formal stages of regulatory review. Both entities have moved forward with documented intent to combine operations, though specific details regarding deal timing, financing structures, and post-merger governance remain contained in the regulatory documentation.
This combination reflects ongoing consolidation trends within healthcare technology and domestic pharmaceutical sectors, where investors and operators increasingly seek to integrate advanced analytics and AI capabilities with core healthcare and manufacturing operations. The $1 billion valuation provides market perspective on Power Analytics' perceived value within the combined entity structure.
The SPAC merger represents a notable pairing of a domestic pharmaceutical manufacturing focus with artificial intelligence and analytics capabilities. Power Analytics Global Corp.'s technology platform would complement the strategic objectives of the Drugs Made In America initiative, which emphasizes domestic production and supply chain resilience in the pharmaceutical sector.
The filing of merger plans with U.S. regulators indicates the transaction has advanced to formal stages of regulatory review. Both entities have moved forward with documented intent to combine operations, though specific details regarding deal timing, financing structures, and post-merger governance remain contained in the regulatory documentation.
This combination reflects ongoing consolidation trends within healthcare technology and domestic pharmaceutical sectors, where investors and operators increasingly seek to integrate advanced analytics and AI capabilities with core healthcare and manufacturing operations. The $1 billion valuation provides market perspective on Power Analytics' perceived value within the combined entity structure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.